1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.
2Department of Neurological Surgery, Na Homolce Hospital, Prague, Czech Republic.
J Neurosurg. 2021 Jun 18;136(1):109-114. doi: 10.3171/2020.12.JNS202814. Print 2022 Jan 1.
The management of neurofibromatosis type 2 (NF2)-associated meningiomas is challenging. The role of Gamma Knife radiosurgery (GKRS) in the treatment of these tumors remains to be fully defined. In this study, the authors aimed to examine the role of GKRS in the treatment of NF2-associated meningiomas and to evaluate the outcomes and complications after treatment.
Seven international medical centers contributed data for this retrospective cohort. Tumor progression was defined as a ≥ 20% increase from the baseline value. The clinical features, treatment details, outcomes, and complications were studied. The median follow-up was 8.5 years (range 0.6-25.5 years) from the time of initial GKRS. Shared frailty Cox regression was used for analysis.
A total of 204 meningiomas in 39 patients treated with GKRS were analyzed. Cox regression analysis showed that increasing the maximum dose (p = 0.02; HR 12.2, 95% CI 1.287-116.7) and a lower number of meningiomas at presentation (p = 0.03; HR 0.9, 95% CI 0.821-0.990) were predictive of better tumor control in both univariable and multivariable settings. Age at onset, sex, margin dose, location, and presence of neurological deficit were not predictive of tumor progression. The cumulative 10-year progression-free survival was 94.8%. Radiation-induced adverse effects were noted in 4 patients (10%); these were transient and managed medically. No post-GKRS malignant transformation was noted in 287 person-years of follow-up.
GKRS achieved effective tumor control with a low and generally acceptable rate of complications in NF2-associated meningiomas. There did not appear to be an appreciable risk of post-GKRS-induced malignancy in patients with NF2-treated meningiomas.
神经纤维瘤病 2 型(NF2)相关脑膜瘤的治疗颇具挑战性。伽玛刀放射外科(GKRS)在这些肿瘤治疗中的作用仍有待充分明确。本研究旨在探讨 GKRS 在 NF2 相关脑膜瘤治疗中的作用,并评估治疗后的结果和并发症。
该回顾性队列研究纳入了来自 7 家国际医学中心的数据。肿瘤进展定义为与基线值相比增加≥20%。研究了患者的临床特征、治疗细节、结果和并发症。从初次 GKRS 开始,中位随访时间为 8.5 年(范围 0.6-25.5 年)。采用共享脆弱性 Cox 回归进行分析。
共分析了 39 例患者的 204 个脑膜瘤,这些患者接受了 GKRS 治疗。Cox 回归分析显示,最大剂量的增加(p=0.02;HR 12.2,95%CI 1.287-116.7)和较低的脑膜瘤初诊数量(p=0.03;HR 0.9,95%CI 0.821-0.990)在单变量和多变量环境中均与更好的肿瘤控制相关。发病年龄、性别、边缘剂量、位置和是否存在神经功能缺损均与肿瘤进展无关。10 年无进展生存率为 94.8%。4 例(10%)患者出现放射性不良反应,均为短暂性且经药物治疗后缓解。在 287 人年的随访中,未发现 GKRS 后恶性转化。
GKRS 对 NF2 相关脑膜瘤的肿瘤控制有效,并发症发生率低且总体可接受。在接受 GKRS 治疗的 NF2 患者中,似乎没有明显的因 GKRS 引起的恶性肿瘤风险。